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Background
Nasal carriers of Staphylococcus aureus are at increased risk for health care–associated 
infections with this organism. Decolonization of nasal and extranasal sites on hos-
pital admission may reduce this risk.
Methods
In a randomized, double-blind, placebo-controlled, multicenter trial, we assessed 
whether rapid identification of S. aureus nasal carriers by means of a real-time poly-
merase-chain-reaction (PCR) assay, followed by treatment with mupirocin nasal 
ointment and chlorhexidine soap, reduces the risk of hospital-associated S. aureus 
infection.
Results
From October 2005 through June 2007, a total of 6771 patients were screened on 
admission. A total of 1270 nasal swabs from 1251 patients were positive for S. aureus. 
We enrolled 917 of these patients in the intention-to-treat analysis, of whom 808 
(88.1%) underwent a surgical procedure. All the S. aureus strains identified on PCR 
assay were susceptible to methicillin and mupirocin. The rate of S. aureus infection 
was 3.4% (17 of 504 patients) in the mupirocin–chlorhexidine group, as compared 
with 7.7% (32 of 413 patients) in the placebo group (relative risk of infection, 0.42; 
95% confidence interval [CI], 0.23 to 0.75). The effect of mupirocin–chlorhexidine 
treatment was most pronounced for deep surgical-site infections (relative risk, 0.21; 
95% CI, 0.07 to 0.62). There was no significant difference in all-cause in-hospital mor-
tality between the two groups. The time to the onset of nosocomial infection was 
shorter in the placebo group than in the mupirocin–chlorhexidine group (P = 0.005).
Conclusions
The number of surgical-site S. aureus infections acquired in the hospital can be re-
duced by rapid screening and decolonizing of nasal carriers of S. aureus on admis-
sion. (Current Controlled Trials number, ISRCTN56186788.)
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Nasal carriers of high numbers of Staphylococcus aureus organisms have a risk of health care–associated infection with 
this microorganism that is three to six times the 
risk among noncarriers and low-level carriers.1-3 
More than 80% of health care–associated S. aureus 
infections are endogenous.4-6
Intranasal application of mupirocin has been 
shown to be effective for the decolonization of this 
microbe and the prevention of invasive S. aureus 
infections in patients receiving long-term dialysis 
treatment.7-10 However, in other nonsurgical pa-
tients, mupirocin had no effect on the rate of 
health care–associated S. aureus infections.11 Mupi-
rocin nasal ointment was reported to be effective 
in preventing surgical-site infections in surgical 
patients, but this study used a historical control 
group.12 Two randomized, controlled trials failed 
to show a reduction in rates of surgical-site infec-
tion in orthopedic and general-surgery popula-
tions, although a subgroup analysis in one of 
these studies suggested that intranasal mupiro-
cin may be effective in preventing health care–
associated S. aureus infections in carriers of this 
organism.13,14
Several explanations have been offered for these 
failures. In some studies, failure of decolonization 
may have been due to the timing of treatment. 
If decolonization is started only after the results 
of screening cultures become available, health 
care–associated infections may already be incu-
bating and may therefore be difficult to prevent. 
With the development of rapid screening tests for 
S. aureus, the carrier status can be assessed within 
hours after admission.15-17 Another explanation 
could be that nasal carriers of S. aureus are also 
colonized at extranasal sites.18 It is unlikely that 
nasal application of mupirocin will directly affect 
these sites. However, decolonization of the skin 
can be achieved by washing with disinfecting soap, 
such as chlorhexidine gluconate products.19
We conducted a randomized, double-blind, 
placebo-controlled, multicenter clinical trial in 
which we rapidly identified nasal carriers of S. au-
reus by real-time polymerase-chain-reaction (PCR) 
assay on admission. In S. aureus carriers only, we 
assessed whether decolonization of the nostrils 
with mupirocin ointment and of the skin with 
chlorhexidine gluconate soap could prevent hos-
pital-associated infections with S. aureus.
Me thods
Study Design
The study was a randomized, double-blind, place-
bo-controlled clinical trial, conducted at three uni-
versity hospitals and two general hospitals in the 
Netherlands. From October 2005 through June 
2007, we screened patients who were admitted to 
the departments of surgery and internal medicine, 
where the risk for S. aureus infection is high. The 
primary outcome of the trial was the cumulative 
incidence of hospital-associated S. aureus infections. 
Secondary outcome measures included all-cause 
in-hospital mortality, duration of hospitalization, 
and time from admission to the onset of health 
care–associated S. aureus infections. The institu-
tional ethics committee at each center approved 
the protocol. Oral informed consent was obtained 
at the time of screening. Once a patient was ran-
domly assigned to decolonization with either mupi-
rocin–chlorhexidine or placebo, written informed 
consent was obtained. The manufacturers of the 
products provided the trial medications and pla-
cebo at no cost but did not influence the study de-
sign, data collection, analysis, writing, or decision 
to submit the results for publication.
Inclusion and Exclusion Criteria
Patients were screened by trained nursing staff for 
nasal carriage of S. aureus either immediately on 
admission or during the week before admission, 
with decolonization therapy begun at the time of 
admission. The inclusion criterion for screening 
was the expectation that a patient would remain 
hospitalized for at least 4 days in one of the par-
ticipating departments (internal medicine, cardio-
thoracic surgery, vascular surgery, orthopedics, 
gastrointestinal surgery, or general surgery). The 
exclusion criterion for screening was an age of less 
than 18 years. Inclusion criteria for randomiza-
tion were nasal carriage of S. aureus as determined 
by real-time PCR and the ability to start the inter-
vention within 24 hours after the patient’s admis-
sion to a participating ward. The expected duration 
of hospitalization was estimated again immedi-
ately before randomization and had to be at least 
4 days. Exclusion criteria for randomization were 
the presence of active infection with S. aureus at 
the time of randomization, known allergy to mupi-
rocin or chlorhexidine, pregnancy, breast-feeding, 
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use of mupirocin in the preceding 4 weeks, and 
the presence of a nasal foreign body.
Randomization
Patients were randomly assigned in a 1:1 ratio to 
either active treatment with mupirocin ointment 
2% (Bactroban, GlaxoSmithKline) in combination 
with chlorhexidine gluconate soap, 40 mg per mil-
liliter (Hibiscrub, Mölnlycke), or placebo ointment 
in combination with placebo soap. Placebo soap 
and ointment were identical to the active treatment 
except for the active ingredients. A single list of 
random numbers with a permuted-block design 
was generated by an independent statistician and 
distributed to all participating centers.
Enrollment and Follow-up
Patients were asked to participate by a member of 
the trial team. Immediately after providing written 
informed consent, the patient was assigned to ei-
ther the active treatment or the placebo according 
to the randomization list, and the first dose of 
nasal ointment was applied. Nasal ointment was 
applied twice daily, and the soap was used daily 
for a total-body wash. The duration of the study 
treatment was 5 days, irrespective of the timing 
of any interventions. Patients who were still hos-
pitalized after 3 weeks and those still hospital-
ized after 6 weeks received a second and third 
course of the same trial medication, respectively.
The follow-up period for S. aureus infection was 
the first 6 weeks after discharge. We defined the 
time to infection as the time from randomization 
to the onset of infection. Data were censored when 
follow-up for S. aureus infection ended or at the 
time of death. Time periods for the end points of 
length of hospital stay and mortality were mea-
sured from the primary admission until 6 weeks 
after discharge from the primary admission. If 
a patient was readmitted to the hospital within 
6 weeks after discharge from the primary admis-
sion, the number of hospital days during the sub-
sequent admission were included in the calcula-
tion of length of stay.
Patients were monitored for hospital-acquired 
S. aureus infection by means of microbiologic cul-
tures. Attending physicians were encouraged to 
obtain culture samples if infection was suspected. 
If a culture grew S. aureus, the patient’s medical 
record was reviewed to distinguish infection from 
colonization and to determine whether the infec-
tion was health care–associated according to cri-
teria established by the Centers for Disease Con-
trol and Prevention.20 The results of all clinical 
cultures performed during the follow-up period 
were also documented. In surgical patients, stan-
dard presurgical prophylactic antimicrobial ther-
apy was given according to the local hospital 
guidelines.
Microbiologic Results
To screen patients for S. aureus carriage, a dry, ster-
ile rayon swab (Becton Dickinson) was rotated 
four times in each nostril. The swab was placed in 
100 μl of saline and centrifuged. Part of the sam-
ple was processed for real-time PCR, and part was 
inoculated onto a blood agar plate, to allow nasal 
and infecting strains to be compared in order to 
determine whether an infection was endogenous 
or exogenous. Culture results were not used to as-
sess eligibility for randomization. Cultured strains 
were genotyped by means of pulsed-field gel elec-
trophoresis to compare them on a clonal level, 
and results were evaluated according to standard 
criteria.21 Further details on the microbiologic 
testing are included in the Supplementary Appen-
dix, available with the full text of this article at 
NEJM.org.
Statistical Analysis
On the basis of previous studies, the estimated 
cumulative incidence of health care–associated 
S. aureus infections in carriers of S. aureus is 6%. 
We originally planned to enroll 1800 subjects for 
randomization to achieve a power of 80% with a 
two-tailed type I error rate of 0.05 and a reduc-
tion of 50% in health care–associated S. aureus 
infections. After 860 patients had been enrolled, 
a perceived change in the cumulative incidence of 
serious S. aureus infections was reported in one of 
the participating centers. On request, the institu-
tional ethics committee at each center approved 
a sequential analysis of the accumulated data set 
by an independent statistician. Analysis of the data 
from the first 400 patients showed that the upper 
boundary was crossed; thus, there was sufficient 
evidence to conclude that the difference in out-
comes between the two study groups was sig-
nificant. At the time of the sequential analysis, 
additional patients had already undergone ran-
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domization, and the data for these patients were 
added to the final analysis. The analysis was strat-
ified according to center and was based on the 
intention-to-treat principle.
R esult s
Study Population
In total, 6771 patients were screened for the pres-
ence of S. aureus in the nasal passages. Results 
were positive for S. aureus on real-time PCR in 
1270 samples (18.8%) obtained from 1251 patients. 
Of the 918 patients who underwent randomiza-
tion, 1 withdrew consent and was excluded from 
the analysis (Fig. 1). Six patients in the mupirocin–
chlorhexidine group and 11 patients in the pla-
cebo group received a second or third course of 
treatment. Table 1 shows the baseline character-
istics of the patients.
Study Outcomes
Figure 2 shows the results of the sequential 
analy sis of the cumulative data. The data cross 
the upper boundary, indicating that there is suf-
ficient evidence that the difference in outcome 
between the two treatment groups is significant 
(P = 0.008). (A detailed description of this analy-
sis is available in the Supplementary Appendix.)
The cumulative incidence of health care–asso-
ciated S. aureus infection was significantly lower 
in the mupirocin–chlorhexidine group than in the 
placebo group (Table 2). Among the 917 patients 
who underwent randomization, 49 had hospital-
acquired S. aureus infections: 17 (3.4%) in the 
mupirocin–chlorhexidine group and 32 (7.7%) in 
the placebo group (relative risk with mupirocin–
chlorhexidine, 0.42; 95% confidence interval [CI], 
0.23 to 0.75). In the sequential analysis we cor-
rected for the imbalance between the groups with 
respect to the proportion of immunocompromised 
patients, but this did not affect the outcome. The 
number of patients who would need to be screened 
and the number of S. aureus carriers who would 
need to be treated to prevent one hospital-acquired 
S. aureus infection were 250 and 23, respectively.
Logistic-regression analysis showed no signifi-
cant difference in the primary outcome between 
surgical and nonsurgical patients. The number of 
nonsurgical patients was small (109 of the 917 
patients included in the analysis [11.9%]). Out-
6 col
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Figure 1. Study Enrollment and Randomization.
Of the 918 patients who underwent randomization, 1 was inadvertently assigned to treatment with mupirocin–chlor-
hexidine despite a nasal swab that was negative for Staphylococcus aureus on polymerase-chain-reaction (PCR) assay.
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comes for the surgical and nonsurgical patients 
are presented separately in Table A in the Supple-
mentary Appendix. Deep surgical-site infections 
were most frequent (Table 2). Among the surgi-
cal patients, this type of infection occurred sig-
nificantly less frequently in the 441 patients in 
the mupirocin–chlorhexidine group than in the 
367 patients in the placebo group (4 infections 
[0.9%] vs. 16 [4.4%]; relative risk, 0.21; 95% CI, 
0.07 to 0.62).
Of the 49 strains causing infection, 47 were 
available for molecular typing to determine wheth-
er the infection had an endogenous or exogenous 
source. The results of molecular typing are shown 
in Table 2.
The time to infection with S. aureus was signifi-
cantly shorter in the placebo group than in the 
mupirocin–chlorhexidine group (P = 0.005 by the 
log-rank test). Figure 3 shows the cumulative haz-
ard of hospital-acquired S. aureus infection in both 
study groups.
The mean duration of hospitalization was sig-
nificantly shorter in the mupirocin–chlorhexidine 
group than in the placebo group (crude estimate, 
12.2 vs. 14.0 days; P = 0.04). Crude estimates of the 
median duration of hospitalization were 9 days 
in the mupirocin–chlorhexidine group and 10 days 
in the placebo group (P = 0.08). All-cause in-hos-
pital mortality did not differ significantly between 
the groups (2.6% in the mupirocin–chlorhexidine 
group and 3.1% in the placebo group; relative risk 
with mupirocin–chlorhexidine, 0.82; 95% CI, 0.37 
to 1.78). Of the 13 patients in the mupirocin–
chlorhexidine group who died, 1 had a hospital-
acquired S. aureus infection. Of the 13 patients in 
the placebo group who died, 3 had a hospital-
Table 1. Baseline Characteristics of the 917 Study Patients.
Characteristic
Mupirocin–Chlorhexidine 
(N = 504)
Placebo 
(N = 413) P Value
Mean (±SD) age — yr 61.8±13.9 62.8±13.3 0.25
Male sex — no. (%) 331 (65.7) 251 (60.8) 0.13
Hospital service — no. (%)
Surgery 441 (87.5) 367 (88.9) 0.53
Internal medicine 63 (12.5) 46 (11.1) 0.53
Admission during month before current admission — 
no./total no. (%)
86/503 (17.1) 67/411 (16.3) 0.76
McCabe score at admission*
Median 1 1
Interquartile range 1–2 1–2
Underlying disorder — no./total no. (%)
Diabetes mellitus type 1 or 2 112/503 (22.3) 71/412 (17.2) 0.06
Disorder requiring continuous ambulatory peritoneal 
dialysis
7/504 (1.4) 4/413 (1.0) 0.57
Renal insufficiency 24/504 (4.8) 23/413 (5.6) 0.57
Immunodeficiency† 19/504 (3.8) 31/413 (7.5) 0.01
Liver-function disorder 25/504 (5.0) 22/413 (5.3) 0.80
Malignant condition 63/504 (12.5) 46/413 (11.2) 0.54
Skin disease 52/501 (10.4) 58/408 (14.2) 0.08
Antibiotic therapy — no./total no. (%)
At time of admission 17/504 (3.4) 16/413 (3.9) 0.69
During month before admission 41/500 (8.2) 28/408 (6.9) 0.46
* We used the McCabe score, as modified by Doern et al.,22 to classify the severity of the underlying disease as follows: 
1, nonfatal; 2, possibly fatal; 3, ultimately fatal; and 4, rapidly fatal.
† Details concerning the definition of immunodeficiency are available in the Methods section of the Supplementary 
Appendix.
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acquired S. aureus infection. These three patients 
had undergone cardiothoracic surgery, whereas 
none of the patients in the mupirocin–chlorhex-
idine group who underwent cardiothoracic sur-
gery died.
Microbiologic Results
We screened 6771 swabs obtained from 6496 pa-
tients to identify nasal carriers of S. aureus. The 
real-time PCR was positive for 1270 samples 
(18.8%). In 1143 (90%) of these samples, S. aureus 
was also cultured. All S. aureus strains that caused 
hospital-acquired infections were susceptible to 
methicillin and mupirocin. The number of cul-
tured microorganisms and the distribution of 
species other than S. aureus did not differ sig-
nificantly between the mupirocin–chlorhexidine 
group and the placebo group.
Adverse Reactions
All reported adverse reactions were due to local 
irritation of the nose or skin and resolved after 
the study treatment was discontinued. (Details 
are available in Table C in the Supplementary Ap-
pendix.)
Discussion
This study shows that rapid detection of S. aureus 
nasal carriage followed by immediate decoloni-
zation of nasal and extranasal sites with mupiro-
cin nasal ointment and chlorhexidine gluconate 
soap significantly reduced the risk of hospital-
acquired S. aureus infections in patients at risk. 
This intervention also significantly reduced the 
mean hospital stay by almost 2 days.
In a recent meta-analysis of clinical trials that 
assessed the effect of nasal mupirocin treatment 
in surgical patients who were S. aureus carriers, the 
eradication of S. aureus reduced the rate of hospi-
tal-associated infection with this pathogen by an 
estimated 45%, but the authors concluded that 
final proof would be needed from a prospective, 
randomized clinical trial.23 A pooled analysis of 
eight studies showed that intranasal mupirocin ap-
plication was associated with a significant reduc-
tion in the infection rate.24 The results of our trial 
provide solid evidence of the preventive effect of 
S. aureus decolonization and a good estimate of the 
size of this effect: the risk of hospital-associated 
S. aureus infections was reduced by nearly 60%.
Our study differs from previous prospective, 
randomized trials in several respects. First, nasal 
carriage of S. aureus was detected rapidly by means 
of real-time PCR at the time of hospital admis-
sion. We believe that the rapidity of this assay 
contributed significantly to the outcome, since it 
allows targeted decolonization treatment to be 
initiated within 24 hours of admission — that is, 
before patients have been exposed to risk factors 
for health care–associated S. aureus infections. 
A second important factor in reducing risk was 
the decontamination of both the nasal passages 
and the skin. It is well known that nasal carriers 
are likely to have extranasal sites that are con-
taminated with the same strain and that carriers 
are at increased risk for endogenous S. aureus in-
fections.18,25,26 We suggest that the use of chlor-
hexidine for simultaneous elimination of S. aureus 
from extranasal sites is needed to achieve the level 
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Figure 2. Results of Group Sequential Analysis.
This analysis was conducted as a double-triangular test, in which the hori-
zontal axis (V) represents the cumulative amount of information available 
and the vertical axis (Z) represents the cumulative effect size. Each point 
(X) represents a group of 100 patients. Assumptions regarding certain vari-
ables determine the boundaries of the test (shown in orange). If the upper 
boundary is crossed, the intervention can be said to have a beneficial ef-
fect; if the lower bound ry is c ossed, the placebo is mor  beneficial. If one 
of the purple dashed lines is crossed, there is no significant difference be-
tween the intervention and the placebo. The blue dashed lines are part of 
the purple boundaries for futility (i.e., equivalence between placebo and in-
tervention); if both blue inner boundaries are crossed, futility would be con-
cluded. The green dashed lines are boundaries that act as a continuity cor-
rection. Z represents the difference between the number of infections 
observed and the number theoretically expected. V represents the variance 
of Z under the null hypothesis (i.e., no difference between intervention and 
placebo). In this case, mupirocin–chlorhexidine significantly reduced the 
cumulative incidence of hospital-acquired S. aureus infection (P = 0.008).
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of prophylaxis observed in this trial. Although this 
additional precaution might not lead to complete 
eradication of the organism, bacterial loads would 
probably be sufficiently reduced to prevent infec-
tion.27 Third, in our study, treatment was contin-
ued for 5 days even when surgery was performed 
during the course of treatment. Also, these treat-
ments were repeated 3 and 6 weeks after admis-
sion for patients who were still in the hospital.
A modification in the study design was neces-
sary because of a perceived change in the overall 
cumulative incidence of S. aureus infections. Since 
an independent statistician designed and analyzed 
the data with no foreknowledge, the switch to a 
sequential design probably did not influence the 
outcomes of the study.
No significant difference in the cumulative 
incidence of hospital-associated S. aureus infections 
was found between surgical and nonsurgical pa-
tients. However, the reduction in these infections 
that was achieved with this intervention was most 
evident among the surgical patients (see Table A 
in the Supplementary Appendix). For such pa-
tients, screening and decolonization of carriers 
provide a clear benefit. Since the proportion of 
nonsurgical patients in this trial was only 11.9%, 
and the cumulative incidence of S. aureus infec-
tions was only 2.2% in the nonsurgical patients 
who received placebo, inferences about nonsur-
gical patients are difficult to make. Further re-
search involving larger cohorts at risk is required 
to assess the benefit of this strategy among non-
surgical patients.
Since mortality was defined in this study as 
all-cause mortality, excess mortality due to S. au-
reus infections had to be very high to result in 
significant differences between the study groups. 
Of the 26 patients who died, 4 had a hospital-
associated S. aureus infection; 3 of these 4 patients 
received placebo and underwent cardiothoracic 
surgery. In contrast, none of the patients who re-
ceived mupirocin–chlorhexidine and underwent 
cardiothoracic surgery died. A total of 6 nonsur-
gical patients in the mupirocin–chlorhexidine 
group died versus 1 in the placebo group, but none 
of these deaths were associated with S. aureus in-
fections. However, since the numbers are small 
and the subgroups were not predefined, these data 
should be interpreted with caution.
Mupirocin and chlorhexidine are considered to 
be relatively safe. However, since S. aureus strains 
can become resistant to mupirocin, we recom-
mend restricting the use of this agent to known 
carriers who are at risk for infection.28 For screen-
ing purposes, priority should be given to tests with 
high specificity, thus limiting the number of false 
positive results and the unnecessary use of mupi-
rocin and chlorhexidine. The prevalence of meth-
icillin-resistant S. aureus carriage in the Nether-
lands is only 0.03%.29 Although this trial was 
designed to identify and eradicate both methi-
cillin-sensitive and methicillin-resistant S. aureus, 
we did not encounter the latter. Biologically speak-
ing, however, it is plausible that this strategy 
would also be effective in carriers of methicillin-
resistant strains of S. aureus that are susceptible to 
mupirocin. Since carriage patterns may be differ-
ent for the methicillin-resistant strains, throat 
swabs in combination with nasal swabs can be 
considered for identifying carriers of S. aureus.30,31
The intervention we describe did not protect 
patients from all hospital-acquired S. aureus infec-
tions. As we anticipated, it had no or limited ef-
fect on exogenous infections. Our intention was 
to prevent infections with endogenous strains by 
Table 2. Relative Risk of Hospital-Acquired Staphylococcus aureus Infection 
and Characteristics of Infections (Intention-to-Treat Analysis).
Variable
Mupirocin– 
Chlorhexidine 
(N = 504)
Placebo 
(N = 413)
Relative Risk 
(95% CI)*
no. (%)
S. aureus infection 17 (3.4) 32 (7.7) 0.42 (0.23–0.75)
Source of infection†
Endogenous 12 (2.4) 25 (6.1) 0.39 (0.20–0.77)
Exogenous 4 (0.8) 6 (1.5) 0.55 (0.16–1.92)
Unknown 1 (0.2) 1 (0.2)
Localization of infection
Deep surgical site‡ 4 (0.9) 16 (4.4) 0.21 (0.07–0.62)
Superficial surgical site‡ 7 (1.6) 13 (3.5) 0.45 (0.18–1.11)
Lower respiratory tract 2 (0.4) 2 (0.5) 0.82 (0.12–5.78)
Urinary tract 1 (0.2) 0
Bacteremia 1 (0.2) 1 (0.2)
Soft tissue 2 (0.4) 0
* Relative risks are for S. aureus infection in the mupirocin–chlorhexidine group.
† The source of the S. aureus infections was determined by comparing nasal 
strains with strains isolated from the infection site by pulsed-field gel electro-
phoresis.
‡ Data are for surgical patients only: 441 in the mupirocin–chlorhexidine group 
and 367 in the placebo group.
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eradicating these strains from nasal and extra-
nasal sites. However, in some of the patients who 
received mupirocin and chlorhexidine, endoge-
nous infections developed, and it is unclear why 
treatment failed in these patients. More insight 
into the pathogenesis of endogenous infections 
would allow preventive strategies to be further 
enhanced. Also, addressing the problem of cross-
infection from exogenous sources of S. aureus re-
mains a challenge.
In conclusion, hospital-acquired infections with 
S. aureus, especially among surgical patients, can 
be prevented by rapid screening of patients to 
identify those who are nasal carriers and initia-
tion of decolonization treatment in confirmed 
carriers immediately after admission.
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Figure 3. Kaplan–Meier Curves Showing Cumulative Hazard of Hospital-Acquired Staphylococcus aureus Infection  
in the Study Groups.
Data were censored at the end of the follow-up period or at the time of death.
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